• AAPL 189.82
  • TSLA 177.46
  • AMZN 184.7
  • MSFT 420.21
  • INTC 31.85
  • EURUSD 1.0872
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. MX /
  3. NVSN.MX

Novartis AG (NVSN MX) stock market data APIs

₱1655.6 0(0%) as of May 16, 2024

Novartis AG Financial Data Overview

1655.6
1655.6
-
1655.6
1655.6
1525.4684-1787.1241
3 507 538 M
22.5743
2 040 M
47 733 M
72.1379
0.0386
0.468
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'NVSN',
Type: 'Common Stock',
Name: 'Novartis AG',
Exchange: 'MX',
CurrencyCode: 'MXN',
CurrencyName: 'Mexican Peso',
CurrencySymbol: '₱',
CountryName: 'Mexico',
CountryISO: 'MX',
OpenFigi: NULL,
ISIN: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - General',
CUSIP: NULL,
}

Novartis AG Fundamental Data is available in our Financial Data APIs

  • Net Revenue 47 733 M
  • EBITDA 18 944 M
  • Earnings Per Share 73.34
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Novartis AG Earnings via APIs

  • Latest Release 2024-03-26
  • EPS/Forecast NaN

Get Novartis AG End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Novartis AG latest news via APIs

Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash

Novartis Pharma AG Novartis secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 65% acceptance threshold Settlement of the shares tend...

Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA

Novartis Pharma AG Primary results of the Scemblix® ASC4FIRST pivotal Phase III study in first-line Ph+ CML-CP supporting third US FDA Breakthrough Therapy designation, to be detailed in the ASCO Pr...
Do you have any questions?
support@eodhistoricaldata.com